If Protara secures approval for TARA-002 in NMIBC, it would become the first drug in its class to get the regulatory greenlight.

MSD said that TroFuse-005 is the first global Phase III trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients and the first and only ...

Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction.

Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab and cemiplimab for metastatic melanoma failed to reach statistical significance for the primary endpoint.